Pharmaceutical Business review

SAFC launches new cell line for biopharmaceutical production

The new cell line which is glutamine synthetase (GS) knockout CHO cell line shortens bioproduction times in early development, improving the speed-to-market and cost efficiency.

CHOZN GS has been developed using SAFC’s proprietary CompoZr ZFN technology that inactivates the glutamine synthetase gene rendering the cells dependent on L-glutamine.

The parental cell line is cGMP banked using Animal Component Free (ACF), Chemically Defined (CD) media and has extensive viral testing, the company said.